PMC:7408073 / 37657-38007 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T225","span":{"begin":213,"end":224},"obj":"Body_part"}],"attributes":[{"id":"A225","pred":"fma_id","subj":"T225","obj":"http://purl.org/sig/ont/fma/fma69050"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T83","span":{"begin":213,"end":224},"obj":"Body_part"}],"attributes":[{"id":"A83","pred":"uberon_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/UBERON_0002049"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1432","span":{"begin":290,"end":294},"obj":"Gene"},{"id":"1436","span":{"begin":249,"end":253},"obj":"Gene"},{"id":"1437","span":{"begin":192,"end":196},"obj":"Gene"},{"id":"1438","span":{"begin":9,"end":13},"obj":"Gene"},{"id":"1450","span":{"begin":101,"end":105},"obj":"Species"},{"id":"1451","span":{"begin":109,"end":113},"obj":"Species"},{"id":"1452","span":{"begin":154,"end":160},"obj":"Species"},{"id":"1453","span":{"begin":341,"end":349},"obj":"Species"},{"id":"1467","span":{"begin":332,"end":340},"obj":"Disease"}],"attributes":[{"id":"A1432","pred":"tao:has_database_id","subj":"1432","obj":"Gene:59272"},{"id":"A1436","pred":"tao:has_database_id","subj":"1436","obj":"Gene:116511"},{"id":"A1437","pred":"tao:has_database_id","subj":"1437","obj":"Gene:116511"},{"id":"A1438","pred":"tao:has_database_id","subj":"1438","obj":"Gene:116511"},{"id":"A1450","pred":"tao:has_database_id","subj":"1450","obj":"Tax:10090"},{"id":"A1451","pred":"tao:has_database_id","subj":"1451","obj":"Tax:10116"},{"id":"A1452","pred":"tao:has_database_id","subj":"1452","obj":"Tax:9606"},{"id":"A1453","pred":"tao:has_database_id","subj":"1453","obj":"Tax:9606"},{"id":"A1467","pred":"tao:has_database_id","subj":"1467","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T232","span":{"begin":332,"end":340},"obj":"Disease"}],"attributes":[{"id":"A232","pred":"mondo_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T449","span":{"begin":26,"end":29},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T450","span":{"begin":154,"end":160},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T451","span":{"begin":295,"end":303},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T341","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T342","span":{"begin":254,"end":265},"obj":"Chemical"}],"attributes":[{"id":"A341","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A342","pred":"chebi_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T176","span":{"begin":0,"end":350},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although MasR antagonists has been shown to be safe in acute and chronic in vivo studies either with mice or rats, there are no data on administration in humans and the existence of different MasR subtypes in the vasculature require combinations of MasR antagonists to inhibit an excess of ACE2 activity as for example may occur in COVID-19 patients."}